Walleye Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Walleye Capital’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-22,600	Closed	-$312K	–	3649
2022 Q2	$312K	Sell	22,600 -10,563	-32%	-$169K	0.01%	1296
2022 Q1	$540K	Buy	+33,163	New	+$519K	0.01%	969
2021 Q2	–	Sell	-24,676	Closed	-$570	–	1562
2021 Q1	$570	Sell	24,676 -12,777	-34%	-$356K	0.03%	547
2020 Q4	$925	Buy	37,453 +23,943	+177%	+$793K	0.06%	310
2020 Q3	$560K	Buy	+13,510	New	+$621K	0.06%	370
2020 Q1	–	Sell	-90	Closed	-$11K	–	1862
2019 Q4	$11K	Buy	+90	New	+$8.06K	﹤0.01%	1646

Other funds holding ICPT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Walleye Capital's ICPT Position: Q3 2022 in Review

Walleye Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2022, closing a stake of 22,600 shares — an estimated $312K sold.

Walleye Capital first reported a position in ICPT in Q4 2019 and held it in 6 quarters. The position peaked at $560K in Q3 2020. 156 funds tracked by Wall St. Rank hold ICPT as of Q3 2022.

Walleye Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
Walleye Capital sold 22,600 Intercept Pharmaceuticals, Inc. shares in Q3 2022, an estimated $312K.
Walleye Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2019 and held it in 6 quarters.
Walleye Capital's Intercept Pharmaceuticals, Inc. position peaked at $560K in Q3 2020.
156 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2022.

Based on Walleye Capital's 13F filing for Q3 2022, filed 14 Nov 2022.